Skip to Content

Scientists Cure Fragile X in Mice

A similar approach might soon be tested in humans.
December 20, 2007

Tweaking the production of a single gene can relieve most symptoms of Fragile X syndrome–the most common inherited cause of mental retardation and autism–in a mouse model of the disease.

Fragile X is linked to mutations in a gene on the X chromosome called FMR1. One theory of the disease is that mutations in this gene lead to overexpression of a specific receptor in the brain. So Mark Bear, a neuroscientist at MIT who led the work, and his colleagues engineered mice with a similar mutation in FMR1 to produce less of that receptor. The engineered animals suffered fewer seizures–a hallmark of Fragile X–and had a normal brain structure compared with their diseased counterparts.

While it’s not yet clear if the findings will translate to humans, scientists hope to learn the answer quickly. Drugs that inhibit this receptor already exist, and Bear has formed a company, Seaside Therapeutics, in Cambridge, MA, to test these drugs in clinical trials.

According to an article at Nature News,

Seaside Therapeutics has applied to the US Food and Drug Administration to test a compound, one of several mGluR antagonists licenced from Merck, in adult humans. If approved, drug trials could start as early as next year–but this class of drugs has traditionally produced mixed results and no compounds are currently approved for any condition.

Bear says that the findings might also apply to autism:

Only a small percentage of people with autism have the fragile-X mutation, but many people with fragile X satisfy the diagnostic criteria for autism. “I’d be extremely pleased if all we accomplished was correcting fragile X in humans,” says Bear. “But we think and it’s possible that this work on fragile X could extend into autism in general.”

Still, some questions remain. Mark Hirst, scientific advisor to the United Kingdom’s Fragile X Society, told the BBC,

“Whilst we know that many proteins are regulated by the fragile X protein, and are therefore disrupted in fragile X individuals, mGluR5 seems to be one of the most important.”

However, he stressed that the mice in the study had benefited from reduced levels of mGluR5 throughout their development–something it would … not be able to replicate in a human drug treatment.

He added: “We must not take our eye off the other proteins that are mis-regulated, as the basis of fragile X syndrome is likely to be more complex and involve other pathways.”

Keep Reading

Most Popular

Russian servicemen take part in a military drills
Russian servicemen take part in a military drills

How a Russian cyberwar in Ukraine could ripple out globally

Soldiers and tanks may care about national borders. Cyber doesn't.

Death and Jeff Bezos
Death and Jeff Bezos

Meet Altos Labs, Silicon Valley’s latest wild bet on living forever

Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner.

ai learning to multitask concept
ai learning to multitask concept

Meta’s new learning algorithm can teach AI to multi-task

The single technique for teaching neural networks multiple skills is a step towards general-purpose AI.

mouse engineered to grow human hair
mouse engineered to grow human hair

Going bald? Lab-grown hair cells could be on the way

These biotech companies are reprogramming cells to treat baldness, but it’s still early days.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.